FIGS 배당 및 자사주 매입
배당 기준 점검 0/6
FIGS 배당금을 지급한 기록이 없습니다.
핵심 정보
n/a
배당 수익률
0.9%
자사주 매입 수익률
| 총 주주 수익률 | 0.9% |
| 미래 배당 수익률 | 0% |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | n/a |
최근 배당 및 자사주 매입 업데이트
Recent updates
FIGS: International Expansion And Margin Recovery Will Drive Future Upside Potential
FIGS' analyst fair value estimate has been raised from $16.31 to $17.75 as analysts point to higher price targets following Q4 results that exceeded expectations, perceived progress on profitable growth, and ongoing opportunities in areas such as international expansion and product initiatives. Analyst Commentary Recent research on FIGS points to a mix of optimism around growth drivers and discipline on profitability, alongside some caution about margins returning to prior levels.FIGS: International Expansion And Q4 Execution Are Expected To Sustain Upside Potential
Analysts have lifted the FIGS fair value estimate from $20.00 to $22.00, reflecting higher modeled revenue growth, a richer future P/E multiple, and Street research that points to momentum following recent earnings and international expansion commentary. Analyst Commentary Recent Street commentary around FIGS has turned more constructive, with several bullish analysts adjusting their price targets higher and revisiting their views after the latest quarterly update.FIGS: International Expansion And Margin Recovery Efforts Will Drive Upside Potential
Narrative Update on FIGS The updated analyst price target for FIGS reflects a modest recalibration in the model inputs. Recent Street research citing Q4 outperformance, improving profitability and customer trends, and longer term opportunities around international expansion and scaling revenue helps explain why analysts continue to refine their $8 to $20 target range for the stock.FIGS: International Expansion And Margin Recovery Efforts Will Likely Cap Near Term Upside
Narrative Update on FIGS The analyst fair value estimate for FIGS has moved from $9.81 to $16.31 as analysts factor in a series of higher price targets and upgrades that highlight international expansion, margin recovery efforts, and what they describe as sustained recovery and strong momentum following recent Q4 results. Analyst Commentary Recent research on FIGS centers on how the company executes on growth opportunities while working to restore profitability metrics, with price target changes reflecting different views on how quickly that balance can be achieved.FIGS: Q4 Execution And Specialty Retail Tailwinds Are Expected To Drive Upside
The analyst fair value estimate for FIGS has increased to $20.00 from $15.00, as analysts point to Q4 earnings strength, improved profitability assumptions, and confidence that the company’s platform can support higher long term revenue potential. Analyst Commentary Recent research on FIGS has turned more constructive, with several bullish analysts revising their fair value views higher after the latest Q4 print and updated outlook.FIGS: Hold On To A Uniquely Positioned Company
Summary FIGS Inc., a healthcare apparel company, is beginning to reach an inflection point for its growth on the back of a rejected unsolicited bid for the company. The company is strongly positioned with a fortress balance sheet and operations to deliver long term growth - which will require heavy expenses in the near future. The current valuation of $16.97 proves to be rich when compared to valuations of the company using historical precedents of forward PE. The stock is therefore a "HOLD" for the near term. Read the full article on Seeking AlphaFIGS: Higher Multiple Assumptions Will Likely Limit Future Share Price Upside
Analysts have nudged their price expectations for FIGS higher, with a modest lift in fair value and future P/E assumptions helping to raise the average price target by about $0.50 as they factor in slightly stronger revenue growth and profit margin potential. Analyst Commentary Recent Street commentary around FIGS points to a mixed but generally constructive stance, with modest price target increases set against ongoing questions about execution and sector risks.FIGS: Demand Uncertainty In Specialty Retail Will Constrain Future Share Performance
Analysts have raised their FIGS fair value estimate from about $4.00 to roughly $6.20 per share. This reflects updated assumptions for revenue growth, profit margins, and the future P/E multiple that are in line with recent price target increases from firms such as Morgan Stanley, Barclays, and Roth Capital.FIGS: Raised Outlook Will Rely On Specialty Retail Tailwinds Into 2026
Narrative Update Analysts have inched up their price targets on FIGS into the high single digit to low double digit US$ range, citing recent research that points to more constructive views on specialty retail through 2026 and firm specific discussions that suggest ongoing business momentum. At the same time, our model keeps fair value steady at US$15.00, with slightly higher revenue growth, margin and future P/E assumptions.FIGS: Upgraded Outlook Hinges On Strong Brand And Healthcare Apparel Demand
Analysts have lifted their FIGS fair value estimate from US$8.00 to US$15.00, reflecting updated assumptions for revenue growth, profit margins and future P/E, along with a series of recent price target increases from Barclays, Roth Capital, Morgan Stanley, Goldman Sachs and BTIG. Analyst Commentary Recent Street research around FIGS has leaned more constructive, with several bullish analysts lifting price targets and initiating positive coverage.FIGS: Reduced Discounting Will Likely Cap Upside Despite Recent Business Momentum
Analysts have modestly lowered our FIGS fair value estimate to approximately $9.17 per share from about $9.53, even as they raise price targets into the mid single to low double digits. They cite stronger than expected post Q3 momentum, improving demand trends, and a richer future earnings multiple outlook, despite slightly softer long term growth and margin assumptions.FIGS: Recent Momentum Will Likely Fade As Reduced Discounting Limits Upside
Our FIGS fair value estimate increases to $9.53 from $8.78 as analysts lift price targets following stronger than expected Q3 results, sustained business momentum signals, and a more constructive view on the brand's long term earnings power. Analyst Commentary Street research on FIGS has turned more constructive overall, with several firms lifting price targets and initiating positive coverage following the company’s strong Q3 performance and improving demand indicators.FIGS: Share Price Will Likely Reflect Limited Upside Amid Market Caution
Analysts have raised their fair value estimate for FIGS from $7.74 to $8.78, citing stronger than expected business momentum, improved revenue growth expectations, and expanding profit margins. Analyst Commentary Recent research coverage of FIGS has provided a mix of constructive insights and measured caution as analysts adjust their expectations.FIGS: Future Competitive Pressures Will Likely Limit Further Upside
FIGS’ analyst price target has increased from $6.74 to $7.74 per share. Analysts point to stronger revenue growth expectations and positive trends within the healthcare apparel sector, which support the revised outlook.There's Reason For Concern Over FIGS, Inc.'s (NYSE:FIGS) Massive 28% Price Jump
The FIGS, Inc. ( NYSE:FIGS ) share price has done very well over the last month, posting an excellent gain of 28%. The...FIGS: High Market Expectations May Limit Upside As Momentum Slows
Analysts have slightly reduced their price target for FIGS, lowering it from $6.74 to $6.74. The adjustment reflects steady business fundamentals and persistent confidence in the brand's strong positioning within the healthcare apparel market.Healthcare, E-Commerce And Global Markets Will Fuel Long-Term Success
Analysts have raised their price target for FIGS from $6.42 to $6.74, citing ongoing strength in U.S. healthcare apparel demand and a solid, debt-free balance sheet as supporting factors for the positive adjustment. Analyst Commentary Recent analyst coverage of FIGS has highlighted both encouraging trends and ongoing areas of caution regarding the company's growth trajectory and valuation.Healthcare, E-Commerce And Global Markets Will Fuel Long-Term Success
The notable upward revision in FIGS' fair value reflects improved consensus revenue growth expectations, more than offsetting the impact of a higher discount rate, resulting in an increased analyst price target from $4.86 to $5.85. What's in the News FIGS, Inc.There's Reason For Concern Over FIGS, Inc.'s (NYSE:FIGS) Massive 35% Price Jump
FIGS, Inc. ( NYSE:FIGS ) shareholders have had their patience rewarded with a 35% share price jump in the last month...It Looks Like FIGS, Inc.'s (NYSE:FIGS) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights FIGS to hold its Annual General Meeting on 4th of June CEO Trina Spear's total compensation includes...Subdued Growth No Barrier To FIGS, Inc. (NYSE:FIGS) With Shares Advancing 40%
Those holding FIGS, Inc. ( NYSE:FIGS ) shares would be relieved that the share price has rebounded 40% in the last...Is Now The Time To Look At Buying FIGS, Inc. (NYSE:FIGS)?
FIGS, Inc. ( NYSE:FIGS ), might not be a large cap stock, but it led the NYSE gainers with a relatively large price...FIGS, Inc.: Recommending A Hold Despite Tailwinds
Summary FIGS, Inc. is recommended as a “HOLD” due to subpar financial performance and limited upside potential, despite growth plans and strong social media presence. Expansion into untapped markets and new physical stores, particularly in Philadelphia, are key business drivers for FIGS’ future growth. Financial analysis reveals significant declines in EBITDA, net income, and free cash flow, with only a slight increase in net revenue. Tariff risks pose substantial threats to FIGS, potentially increasing production costs and affecting profit margins and demand. Read the full article on Seeking AlphaFIGS' (NYSE:FIGS) Soft Earnings Don't Show The Whole Picture
The most recent earnings report from FIGS, Inc. ( NYSE:FIGS ) was disappointing for shareholders. While the headline...Figs, Inc. - Slow Growth Is Still Growth
Summary Figs, Inc. is undervalued, as strong private equity interest and a robust balance sheet indicate potential for significant returns. Favorable growth trends in healthcare employment and broader market appeal support optimistic revenue projections for Figs, Inc. Derived equity value suggests a 25% upside from the current share price, highlighting market undervaluation post-IPO. Superior product quality and brand loyalty, coupled with strategic cash reserves, position Figs, Inc. for steady growth and revenue expansion. Read the full article on Seeking AlphaBe Wary Of FIGS (NYSE:FIGS) And Its Returns On Capital
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...FIGS: Enter A White Knight?
Summary FIGS, Inc. faces stagnating sales and plummeting earnings, with recent Q3/2024 revenues shrinking by 1.5% YoY and operating losses mounting. Private equity firm Story3 Capital Partners is rumored to have offered $6 a share for FIGS, causing a pre-market rally; investors should take advantage and sell their shares. FIGS' valuation may be attractive to Story3, trading at 1.2x Fwd EV/Sales, compared to 2.4x for Nike and 4.6x for Lululemon. Management's diversification efforts have failed; a focus on international DTC medical scrubs could be a winning strategy under new ownership. Read the full article on Seeking AlphaFIGS Back To Q1 Prices, But The Name Is Still A Hold
Summary Figs reported disappointing 3Q24 results with a 2% revenue decline and a 13 percentage point drop in adjusted EBITDA margins, leading to a 30% stock price drop. The company's high SG&A expenses and lack of growth make it difficult to compete against lower-priced alternatives, justifying my Hold rating. Questionable $25 million investment in a pre-product healthcare education app raises concerns about capital allocation and potential conflicts of interest. Despite a great product, Figs' lack of expense control and high valuation make it an unattractive investment at current prices. Read the full article on Seeking AlphaThe Price Is Right For FIGS, Inc. (NYSE:FIGS) Even After Diving 26%
FIGS, Inc. ( NYSE:FIGS ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The...FIGS (NYSE:FIGS) May Have Issues Allocating Its Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...If EPS Growth Is Important To You, FIGS (NYSE:FIGS) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...FIGS, Inc.: Growth Potentially Inflecting Upwards
Summary I rate FIGS, Inc. stock as a buy, expecting growth to inflect upwards with orders per buyer potentially more than doubling. FIGS has enhanced top-of-funnel awareness, product innovation, and distribution capacity, driving customer acquisition beyond its core scrub customer base. Margin pressures are temporary; scaling non-scrub products and the high-margin TEAMS business should flip this headwind into a tailwind. Read the full article on Seeking AlphaAt US$5.61, Is FIGS, Inc. (NYSE:FIGS) Worth Looking At Closely?
FIGS, Inc. ( NYSE:FIGS ), is not the largest company out there, but it led the NYSE gainers with a relatively large...Tactical Partnerships And Innovations Propel Brand Expansion And Financial Growth
The partnership with Team USA and innovative product lines like Flare ScrubLegging highlight brand visibility enhancement and market expansion efforts.FIGS Q2 2024 Shows Growth At The Expense Of Margins. The Stock Is Still Overpriced
Summary FIGS' Q2 2024 results showed moderate revenue growth but at the expense of lower margins due to increased spending on products and marketing. The company's lack of cost management and high gross margins make it vulnerable to competition, justifying my Hold rating. Despite some improvement in guidance, the valuation remains unattractive with the stock trading at a high P/E ratio even under optimistic scenarios. I maintain that FIGS is not an opportunity at current prices. Read the full article on Seeking Alpha지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: 과거에 FIGS 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.
배당금 증가: FIGS 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.
배당 수익률 vs 시장
| FIGS 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (FIGS) | n/a |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.2% |
| 업계 평균 (Luxury) | 2.5% |
| 분석가 예측 (FIGS) (최대 3년) | 0% |
주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 FIGS 의 배당 수익률을 평가할 수 없습니다.
고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 FIGS 의 배당 수익률을 평가할 수 없습니다.
주주 대상 이익 배당
수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 FIGS 의 지급 비율을 계산하기에는 데이터가 부족합니다.
주주 현금 배당
현금 흐름 범위: FIGS 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/11 19:00 |
| 종가 | 2026/05/08 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
FIGS, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Adrienne Yih-Tennant | Barclays |
| Robert Drbul | BTIG |
| Brooke Roach | Goldman Sachs |